

TERCICA INC  
Form 8-K  
March 07, 2007

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 03/07/2007**

**Tercica, Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 000-50461**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**26-0042539**  
(IRS Employer  
Identification No.)

**2000 Sierra Point Parkway**  
Suite 400  
Brisbane, CA 94005  
(Address of principal executive offices, including zip code)

**(650) 624-4900**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Edgar Filing: TERCICA INC - Form 8-K

Information to be included in the report

### Item 8.01. Other Events

On March 6, 2007, Tercica, Inc. (the "Company") issued a press release announcing that Tercica, Insmid and Genentech, Inc. have entered a Settlement, License and Development Agreement that resolves all outstanding litigation between the companies, including the patent infringement suits brought by Tercica and Genentech against Insmid in the United States (N.D. Cal.) and United Kingdom, and the unfair business practices suit (E.D. Virginia).

---

#### Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tercica, Inc.

Date: March 07, 2007

By: /s/ Stephen N. Rosenfield

---

Stephen N. Rosenfield  
Executive Vice President of Legal Affairs

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	Press release entitled "Litigation Settlement Reached between Tercica, Genentech and Insmmed", dated March 3, 2007